Partial Recovery of Renal Function in Black Patients with Apparent End-Stage Renal Failure due to Primary Malignant Hypertension

Nephron ◽  
1995 ◽  
Vol 71 (1) ◽  
pp. 29-34 ◽  
Author(s):  
S.H. James ◽  
A.M. Meyers ◽  
F.J. Milne ◽  
S.G. Reinach
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Malignant Hypertension ◽  
Partial Recovery ◽  
End Stage Renal Failure ◽  
Black Patients ◽  
End Stage

Oral and Maxillofacial Manifestations of Mineral and Bone Disorders Associated with Chronic Renal Failure

2017 ◽  
Vol 68 (6) ◽  
pp. 1325-1328
Author(s):  
Andrada Raluca Doscas ◽  
Mihail Balan ◽  
Mihai Liviu Ciofu ◽  
Doriana Agop Forna ◽  
Marius Cristian Martu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Failure ◽  
Renal Function ◽  
Chronic Renal Failure ◽  
Health Concern ◽  
Oral Manifestations ◽  
End Stage Renal Failure ◽  
Brown Tumors ◽  
The Mean ◽  
End Stage

Chronic kidney disease (CKD) is a multifactorial syndrome and a global health concern. As renal function declines, there is a progressive deterioration of mineral homeostasis. Starting from stage 3 of CKD oral manifestations of mineral disorders can occasionally appear and become more frequent and evident in stage 5. We retrospectively analysed 43 patients diagnosed with end stage renal failure undergoing dialysis, hospitalized in our clinic for different oral and maxillofacial pathologies. The mean dialysis period was 5.43 years. Radiographic alterations afecting the jaws were found in all patients. The most common feature was partial or total loss of lamina dura, followed by alterations of the bony trabeculae. 9 patients presented brown tumors which are considered the final stage of secondary hyperparathyroidism associated with renal failure.

scholarly journals Residual renal function with different frequencies of hemodialysis treatment in end-stage renal failure patients

1987 ◽  
Vol 20 (2) ◽  
pp. 105-109
Author(s):  
Kazumasa Shimamatsu ◽  
Satoru Fujimi ◽  
Kaoru Onoyama ◽  
Hiroshi Tsuruda ◽  
Masatoshi Fujishima
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Residual Renal Function ◽  
End Stage Renal Failure ◽  
Hemodialysis Treatment ◽  
End Stage

Pharmacokinetics of Recombinant Hirudin in Hemodialyzed End-stage Renal Failure Patients

1997 ◽  
Vol 77 (04) ◽  
pp. 650-655 ◽  
Author(s):  
R Vanholder ◽  
A Camez ◽  
N Veys ◽  
A Van Loo ◽  
A M Dhondt ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Residual Renal Function ◽  
Hemodialysis Patients ◽  
The Body ◽  
Pharmacokinetic Data ◽  
High Flux ◽  
Recombinant Hirudin ◽  
End Stage Renal Failure ◽  
End Stage

SummaryRecently, hirudin was used for the first time as an anticoagulant during hemodialysis in men. Pharmacokinetic data of this compound in end-stage renal failure are however not available. In this study, the pharmacokinetics of recombinant hirudin (HBW 023) was evaluated in hemodialysis-treated end-stage renal failure patients. HBW 023 was administered as a bolus at the start of a single dialysis (0.02 to 0.08 mg/kg) in 20 patients, and plasma hirudin levels were followed during this and the 5 following dialyses, without additional hirudin administration. The initial dialysis (HDj) was performed with a low flux polysulfone dialyzer; the following dialyses (up to HD6) with a high flux polysulfone dialyzer and regular heparin. Hirudin levels averaged 504.0 ± 214.0 and 527.7 ± 217.1 ng/ml in the middle and at the end of HDj, and then gradually decreased to 15.2 ± 15.2 ng/ml at the end of HD6. Pharmacokinetic data were compared to those obtained in healthy controls (n = 5), receiving the same dose, and reaching the same peak hirudin level. Hirudin half-life was >30 times longer in hemodialysis patients (51.8 ± 15.6 vs. 1.7 ± 1.5 h, p <0.001), whereas area under the curve was >60 times higher (34,669 ± 14,898 vs. 545 ± 205 ng/ml X h, p <0.001). Distribution volume was lower in hemodialysis patients (11.0 ± 3.1 vs. 14.1 ± 2.0 1, p <0.05). Hirudin disappearance rate was the same during high flux polysulfone dialysis as during interdialytic periods. Hirudin removal was markedly higher in those patients still maintaining some residual renal function and parameters of hirudin removal were significantly correlated to residual creatinine clearance. It is concluded that hirudin removal from the body is markedly depressed in hemodialyzed end-stage renal failure patients and that even minor residual renal function may increase this removal rate.

Goodpasture's Syndrome Superimposed on Membranous Nephropathy. A Case Report

1995 ◽  
Vol 18 (12) ◽  
pp. 763-765 ◽  
Author(s):  
S. Thitiarchakul ◽  
S.M. Lal ◽  
A. Luger ◽  
G. Ross
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Case Report ◽  
Basement Membrane ◽  
Severe Hypertension ◽  
Maintenance Hemodialysis ◽  
Aggressive Therapy ◽  
End Stage Renal Failure ◽  
Membranous Glomerulopathy ◽  
End Stage

We describe a patient with idiopathic membranous glomerulopathy who developed acute deterioration in renal function; this was associated with hemoptysis, severe hypertension, and anti-glomerular basement membrane (anti-GBM) antibody in the serum. Despite aggressive therapy with plasmapheresis, cyclophosphamide and prednisone, the patient progressed to end-stage renal failure and is on maintenance hemodialysis.

Nephrotic syndrome

2020 ◽  
Vol 13 (3) ◽  
pp. 159-163
Author(s):  
Thuvaraka Ware
Keyword(s):  
Primary Care ◽  
Renal Failure ◽  
Renal Function ◽  
Nephrotic Syndrome ◽  
Diagnostic Process ◽  
Risk Of Infection ◽  
Rare Presentation ◽  
End Stage Renal Failure ◽  
Increased Risk ◽  
End Stage

Nephrotic syndrome is characterised by proteinuria, hypoalbuminaemia and oedema. The renal function is often normal and symptoms may mimic other common pathologies presenting in the community. The underlying aetiology is more heterogenous in adults compared with children, further confounding the diagnostic process and leading to delays in recognition. It is a relatively rare presentation in primary care, but the consequences of nephrotic syndrome can be significant. Complications include hyperlipidaemia, hypercoaguability, increased risk of infection and end-stage renal failure. It is, therefore, important to diagnose, investigate and manage nephrotic syndrome appropriately.

Predictors of Renal Recovery in Australian and New Zealand end-Stage Renal Failure Patients Treated with Peritoneal Dialysis

2007 ◽  
Vol 27 (2) ◽  
pp. 184-191 ◽  
Author(s):  
Ann-Maree S. Craven ◽  
Carmel M. Hawley ◽  
Stephen P. McDonald ◽  
Johan B. Rosman ◽  
Fiona G. Brown ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Peritoneal Dialysis ◽  
New Zealand ◽  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Patient Death ◽  
Cortical Necrosis ◽  
End Stage Renal Failure ◽  
End Stage

Objectives The aim of this study was to investigate the factors affecting recovery and durability of dialysis-independent renal function following commencement of peritoneal dialysis (PD). Design Retrospective, observational cohort study of the Australian and New Zealand PD patient population. Setting Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. Participants The study reviewed all patients in Australia and New Zealand who commenced PD for treatment of end-stage renal failure between 15 May 1963 and 31 December 2004. Main Outcome Measures The primary outcomes examined were recovery of dialysis-independent renal function and time from PD commencement to recovery of renal function. A secondary outcome measure was time to renal death (patient death or recommencement of renal replacement therapy) following recovery of dialysis-independent renal function. Results 24663 patients commenced PD during the study period. Of these, 253 (1%) recovered dialysis-independent renal function. An increased likelihood of recovery was predicted by autoimmune renal disease, hemolytic-uremic syndrome, paraproteinemia, cortical necrosis, renovascular disease, and treatment in New Zealand. A reduced likelihood of recovery was associated with polycystic kidney disease and indigenous race. Analysis of a contemporary subset of 14743 patients in whom complete data were available for body mass index, smoking, and comorbidities yielded comparable results, except that increasing age was additionally associated with a decreased likelihood of recovery. Of the 253 patients who recovered renal function, 151 (60%) recommenced renal replacement therapy and 49 (19%) died within a median period of 226 days (interquartile range 110 – 581 days). The only significant predictors of continued renal survival after renal recovery were autoimmune renal disease and cortical necrosis. Conclusions Recovery of renal function in patients treated with PD is rare and determined mainly by renal disease type and race. In the majority of cases, recovery is short term. The apparently high rate of early patient death or return to dialysis after recovery of renal function on PD raises questions about the appropriateness of discontinuing PD therapy under such circumstances.

Sign in / Sign up

Export Citation Format

Share Document